A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects

This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult volunteers administered as a single IV dose compared with placebo, across 4 cohorts. The 4 dose cohorts will enroll sequentially. Subjects will be followed for safety from the time of Informed Consent through 360 days post dose.

Study Overview

• Status: Completed
• Conditions: Staphylococcus Aureus
• Intervention / Treatment: Drug: Placebo; Drug: MEDI4893

Detailed Description

This is a phase 1, randomized, double-blind, placebo-controlled, dose-escalation study to evaluate the safety, tolerability and pharmacokinetics of MEDI4893, an extended half-life human monoclonal antibody against Staphylococcus aureus alpha toxin, in healthy adult subjects. Approximately 33 subjects will be enrolled across 4 fixed dose cohorts at 1 study site . This study will last approximately 389 days, constituting a screening period of up to 28 days, 1 day of investigational product administration, and a 360 day safety follow up period.

• Study Type: Interventional
• Enrollment (Actual): 85
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami, Florida, United States
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Age 18 through 65 years at screening.
2. Written informed consent and any locally required authorization (eg, HIPAA) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
3. Females of childbearing age using contraception for at least 28 days prior to receiving the dose of investigational product, and for 1 year after receiving IP.
4. Weight ≥ 45 kg and ≤ 110 kg at screening.
5. Healthy by medical history and physical examination at screening.
6. Systolic blood pressure (BP) < 140 mm Hg and diastolic BP < 90 mm Hg at screening.
7. Normal electrocardiogram (ECG) at screening.
8. Able to complete the 360-day postdose follow-up period as required by the protocol.

Exclusion Criteria:

1. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
2. Employees of the sponsor, clinical study site, or any other individuals involved with the conduct of the study, or immediate family members of such individuals.
3. Acute illness at study entry.
4. Fever 99.5F or higher on day of dosing.
5. Any drug therapy within 7 days prior to Day 1.
6. Blood donation in excess of 400 mL within 6 months prior to study entry.
7. Receipt of immunoglobulin or blood products within 6 months prior to study entry.
8. Receipt of any prior investigational drug or investigational vaccine within 120 days prior to investigational product dosing or planned dosing
9. Receipt of any standard vaccine within 14 days prior to investigational product dosing.
10. Previous receipt of a monoclonal antibody.
11. Receipt of immunosuppressive medications in the prior year or any active or prior history of immunodeficiency. Any course of systemic corticosteroids of more than 7 day duration during the prior year excludes a subject.
12. History of allergic disease or reactions likely to be exacerbated by any component of the investigational product.
13. Previous medical history or evidence of an intercurrent illness that may compromise the safety of the subject in the study.
14. Evidence of any systemic disease on physical examination at screening.
15. Evidence of infection (ie, positive laboratory test result) with hepatitis A, B, or C virus or human immunodeficiency virus (HIV) at screening.

16. Any of the following at screening:

    1. Hemoglobin < 12.0 g/dL for males and < 11.5 g/dL for females.
    2. WBC count < 3,800/mm3.
    3. Platelet count < 140,000/mm3.
    4. AST, ALT, BUN, serum creatinine > upper limit of normal (ULN).
    5. Positive Urine Class A drug screen.
    6. Other abnormal laboratory values in the screening panel, which in the opinion of the principal investigator, are judged to be clinically significant or potentially confound study results.
17. Pregnant or nursing mother.
18. Active alcohol or drug abuse or history of alcohol or drug abuse that, in the opinion of the principal investigator, might compromise subject safety, study safety assessments, or ability of subject to comply with study requirements.
19. Concurrent enrollment in another interventional study.

Study Plan

How is the study designed?

Design Details

• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Placebo
Active Comparator: MEDI4893	Drug: MEDI4893; Human immunoglobulin G1 kappa monoclonal antibody; Other Names: Active comparator

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The occurence of adverse events and serious adverse events.		From the time of informed consent through 360 days post dose
Vital Sign Measurements	blood pressure, heart rate, respiratory rate, temperature	Pre-dose through Study Day 15
Clinical Safety lab measurements	Chemistry, Hematology and urinalysis	from Day 1 (pre-dose) through 90 days post dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacokinetic Assessments - Serum	MEDI4893 Pharmacokinetic parameters.	Pre-dose through 360 days post dose
Anti Drug Antibody (ADA) Assessments - Serum	ADA responses to MEDI4893.	Pre-dose through 360 days post dose

Collaborators and Investigators

• Sponsor: MedImmune LLC
• Investigators: Principal Investigator: Howard Schwartz, M.D., Research Site; Study Director: Hasan Jafri, M.D., MedImmune LLC

Study record dates

Study Major Dates

• Study Start: January 1, 2013
• Primary Completion (Actual): May 1, 2014
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: January 11, 2013
• First Submitted That Met QC Criteria: January 14, 2013
• First Posted (Estimate): January 16, 2013

Study Record Updates

• Last Update Posted (Estimate): July 24, 2014
• Last Update Submitted That Met QC Criteria: July 23, 2014
• Last Verified: July 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Bacterial Infections; Bacterial Infections and Mycoses; Gram-Positive Bacterial Infections; Staphylococcal Infections
• Other Study ID Numbers: CD-ID-MEDI4893-1133